e-learning
resources
Virtual 2021
06.09.2021
Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Severe asthma biologic treatment in the era of COVID-19 – case series
P. Nogueira Costa (Coimbra, Portugal), C. Chaves Loureiro (Coimbra, Portugal)
Source:
Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Session:
Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Session type:
E-poster
Number:
2524
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Nogueira Costa (Coimbra, Portugal), C. Chaves Loureiro (Coimbra, Portugal). Severe asthma biologic treatment in the era of COVID-19 – case series. 2524
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report
Source: Eur Respir J 2006; 28: Suppl. 50, 829s
Year: 2006
Severe asthma: approach to diagnosis and treatment
Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond
Year: 2008
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study
Source: International Congress 2017 – Monitoring asthma control
Year: 2017
Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Biologic therapies in paediatric severe asthma
Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma
Year: 2020
Effective use of corticosteroids in the treatment of plastic bronchitis with hemoptysis in Chinese adults: a nine-year clinical experience
Source: Eur Respir J 2006; 28: Suppl. 50, 44s
Year: 2006
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Super-response to dupilumab therapy in a patient with severe asthma and ABPA – a case report
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011
The use of omalizumab in the management of severe chronic paediatric asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Treatment of severe childhood asthma: what’s the evidence?
Source: Annual Congress 2005 - Difficult asthma in children
Year: 2005
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Omalizumab in severe uncontrolled asthma: two and a half year clinical experience
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children
Source: Eur Respir J 2006; 28: Suppl. 50, 481s
Year: 2006
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept